Risk of thromboembolic events after perioperative chemotherapy versus surgery alone for esophageal adenocarcinoma

Annals of Surgical Oncology

Volumn 19, Issue 2, 2012, Pages 684-692

  Verhage, Roy J J ^a   Van Der Horst, Sylvia ^a   Van Der Sluis, Pieter C ^a   Lolkema, Martijn P J K ^a   Van Hillegersberg, Richard ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; DALTEPARIN; EPIRUBICIN; LOW MOLECULAR WEIGHT HEPARIN;

AGED; AORTA THROMBOSIS; ARTERIAL INSUFFICIENCY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; ESOPHAGUS SURGERY; FEMALE; HEART INFARCTION; HOSPITALIZATION; HUMAN; LUNG EMBOLISM; MALE; MULTIPLE CYCLE TREATMENT; PERIOPERATIVE COMPLICATION; PERIOPERATIVE PERIOD; PORTAL VEIN THROMBOSIS; POSTOPERATIVE PERIOD; STROKE; THROMBOEMBOLISM; VEIN THROMBOSIS;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DEOXYCYTIDINE; EPIRUBICIN; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PERIOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOEMBOLISM;

EID: 84856682877     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2005-8     Document Type: Article

References (18)

1. MB Cook WH Chow SS Devesa 2009 Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005 Br J Cancer 101 855 859 19672254 10.1038/sj.bjc.6605246 1:STN:280:DC%2BD1MrnvVKmug%3D%3D
2. C Bosetti F Levi J Ferlay, et al. 2008 Trends in oesophageal cancer incidence and mortality in Europe Int J Cancer. 122 1118 1129 17990321 10.1002/ijc.23232 1:CAS:528:DC%2BD1cXhslGgsrk%3D
3. C Lepage B Rachet V Jooste J Faivre MP Coleman 2008 Continuing rapid increase in esophageal adenocarcinoma in England and Wales Am J Gastroenterol. 103 2694 2699 18853967 10.1111/j.1572-0241.2008.02191.x
4. D Cunningham WH Allum SP Stenning, et al. 2006 Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med. 355 11 20 16822992 10.1056/NEJMoa055531 1:CAS:528:DC%2BD28Xms1Chsrw%3D
5. TR Evans G Pentheroudakis J Paul, et al. 2002 A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma Ann Oncol. 13 1469 1478 12196374 10.1093/annonc/mdf243 1:STN:280: DC%2BD38vpvV2mtA%3D%3D
6. TA Rich RC Shepard ST Mosley 2004 Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy J Clin Oncol. 22 2214 2232 15169811 10.1200/JCO.2004.08.009 1:CAS:528:DC%2BD2cXpsVWlt7o%3D
7. MA Shah M Capanu G Soff T Asmis DP Kelsen 2010 Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies J Thromb Haemost. 8 1702 1709 20553384 10.1111/j.1538-7836.2010. 03948.x 1:STN:280:DC%2BC3cbisFOksw%3D%3D
8. N Starling S Rao D Cunningham, et al. 2009 Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group J Clin Oncol. 27 3786 3793 19398575 10.1200/JCO.2008.19.4274 1:CAS:528:DC%2BD1MXhtFaitr3E
9. G Agnelli G Bolis L Capussotti, et al. 2006 A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project Ann Surg. 243 89 95 16371741 10.1097/01.sla.0000193959.44677.48
10. AA Khorana GC Connolly 2009 Assessing risk of venous thromboembolism in the patient with cancer J Clin Oncol. 27 4839 4847 19720906 10.1200/JCO.2009.22. 3271 1:CAS:528:DC%2BD1MXhtlKjtLvP
11. MM Oken RH Creech DC Tormey, et al. 1982 Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol. 5 649 655 7165009 10.1097/00000421-198212000-00014 1:STN:280:DyaL3s7kvFOgsw%3D%3D
12. H Schuurmans N Steverink S Lindenberg N Frieswijk JP Slaets 2004 Old or frail: what tells us more? J Gerontol A Biol Sci Med Sci. 59 M962 M965 15472162 10.1093/gerona/59.9.M962
13. National Cancer Institute common terminology criteria for adverse events v.4.03. U.S. Department of Health and Human Services. http://evs.nci.nih.gov/ ftp1/CTCAE/About.html
14. ME Tesselaar J Ouwerkerk MA Nooy FR Rosendaal S Osanto 2004 Risk factors for catheter-related thrombosis in cancer patients Eur J Cancer. 40 2253 2259 15454250 10.1016/j.ejca.2004.06.023 1:STN:280:DC%2BD2cvosFyrsw%3D%3D
15. ED Tetzlaff AM Correa J Baker J Ensor JA Ajani 2007 The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma Cancer. 109 1989 1995 17397035 10.1002/cncr.22626 1:CAS:528:DC%2BD2sXmtV2qs7s%3D
16. D Cunningham N Starling S Rao, et al. 2008 Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med. 358 36 46 18172173 10.1056/NEJMoa073149 1:CAS:528:DC%2BD1cXisFSktg%3D%3D
17. Montagnani F, Turrisi G, Marinozzi C, Aliberti C, Fiorentini G. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2011;14:50-5
18. FJ Fleming MJ Kim RM Salloum KC Young JR Monson 2010 How much do we need to worry about venous thromboembolism after hospital discharge? A study of colorectal surgery patients using the National Surgical Quality Improvement Program database Dis Colon Rectum. 53 1355 1360 20847615 10.1007/DCR. 0b013e3181eb9b0e